Method and composition for hyperthermally treating cells
OwnerGholam A. Peymaninventor
Life of this patent
Estimating the term…
Abstract
A method and composition for hyperthermally treating tumor cells in a patient under conditions that affect tumor stem cells and tumor cells. In one embodiment, the method provides a synergetic effect with chemotherapy.
Claims16
A method of drug delivery and thermal damage to target tumor cells in a patient in need thereof, the method comprising
- administering anti-tumor antibody specific coated nanoparticles to a patient in need thereof,
- thereafter locally administering thermal therapy at the tumor site containing the anti-tumor antibody specific coated nanoparticles, the thermal therapy administered under conditions sufficient to result in
- a first temperature at the tumor site of at least 37° C. to 43° C., and
- thereafter a second temperature at the tumor site of at least one of 43° C. to 58° C., 43° C. to 45° C., 43° C. to 58° C., 45° C. to 50° C., 50° C. to 58° C., 58° C. to 60° C., greater than 58° C., or greater than 60° C.,
- the thermotherapy resulting in specific drug delivery and thermal damage to tumor cells.
A method of targeting tumor stem cells for therapy in a patient in need thereof, the method comprising combining chemotherapy with thermotherapy, the tumor thermotherapy being a stepwise increase in temperature that at relatively lower temperatures primes the tumor stem cells for increased susceptibility to the chemotherapy then, at relatively higher temperatures, kills the primed tumor stem cells with a synergestic combination of the chemotherapy and the thermotherapy.
A method of providing thermotherapy to a cancer patient, the method comprising
- (a) administering to a cancer patient in need thereof a composition comprising at least one biocompatible excipient and a liposome, where the liposome comprises at least one nanoparticle and at least one anticancer drug, optionally conjugated to the at least one nanoparticle, under conditions to provide a concentration of the anticancer drug at a target site sufficient to be amenable to thermal therapy, and
- (b) providing an energy source to measure an acoustic response and to heat the target site to
- (i) a first temperature at the tumor site of at least 37° C. to 43° C., and
- (ii) thereafter a second temperature at the tumor site of at least one of 43° C. to 58° C., greater than 58° C., or greater than 60° C.,
- the thermotherapy resulting in specific drug delivery and thermal damage to tumor cells.
Dependencies are inferred from the claim text.